Usefulness of 18f-FDG PET-CT in Staging, Restaging, and Response Assessment in Pediatric Rhabdomyosarcoma

Donner, Davide; Feraco, Paola; Meneghello, Linda; Rombi, Barbara; Picori, Lorena; Chierichetti, Franca

doi:10.3390/diagnostics10121112

Cited by 7 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a complement to staging, restaging, and response assessment of metastatic RMS, PET/CT imaging has steadily increased in use in the last decade. 11,12 HPE and IHC are necessary for confirming the diagnosis. In our case, FDG-PET/CT revealed solitary skeletal metastasis in the baseline scan.…”

Section: Discussionmentioning

confidence: 99%

Paranasal Sinus Embryonal Rhabdomyosarcoma Metastasizing to Breast and Ovary on PET/CT—A Case Report with the Review of Literature

Singh

Saini

Ora

et al. 2023

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Rhabdomyosarcoma (RMS) is a malignant soft tissue tumor of skeletal muscle origin. The head and neck, urinary tract, and extremities are the common sites of origin. Embryonal, alveolar, pleomorphic, and spindle/sclerosing are subtypes. It is more common in childhood and rare among adults. The incidence and risk factors for this disease are mainly largely unknown. RMS is sporadic in most instances; however, it is attributed to familial syndromes in some situations—its metastasis to the lungs, bone marrow, and lymph nodes. Breast and ovary involvement is scarce. Diagnostic workup mainly includes contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (MRI). However, 18F-fluro-deoxyglucose positron emission tomography (18F-FDG-PET/CT) and PET/MRI are increasing contribution to providing functional insights about tumor biology and improving the diagnostic accuracy of the imaging workup. This report presents a case of the neck's embryonal RMS metastasizing simultaneously to the breast and ovary. PET/CT imaging revealed the unusual pattern, further validated by histopathology.

show abstract

Section: Discussionmentioning

confidence: 99%

Paranasal Sinus Embryonal Rhabdomyosarcoma Metastasizing to Breast and Ovary on PET/CT—A Case Report with the Review of Literature

Singh

Saini

Ora

et al. 2023

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…Rhabdomyosarcomas tend to be moderate in terms of metabolic activity on FDG PET-CT. FDG PET-CT has been shown to be effective as well as more accurate than conventional imaging (bone scan, radiographs, CT, MRI) in staging and restaging rhabdomyosarcoma and this is acknowledged by the NCCN [ 82 , 83 ]. FDG PET-CT has been shown to be useful in monitoring response to therapy for pediatric rhabdomyosarcomas, although it has not been as well studied in adults [ 84 ]. However, the magnitude of metabolic activity pre-treatment does not predict outcome in rhabdomyosarcoma in children [ 85 ].…”

Section: Sarcomasmentioning

confidence: 99%

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Fine

Covington

Koppula

et al. 2022

Cancers

View full text Add to dashboard Cite

PET-CT is an advanced imaging modality with many oncologic applications, including staging, therapeutic assessment, restaging and surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, the potential pitfalls and nuances that characterize these applications, and guidelines for image interpretation. Tumor-specific clinical information and representative PET-CT images are provided. The current, sixth article in this series addresses PET-CT in an evaluation of aggressive cutaneous malignancies, sarcomas and neuroendocrine tumors. A discussion of the role of FDG PET for all types of tumors in these categories is beyond the scope of this review. Rather, this article focuses on the most common malignancies in adult patients encountered in clinical practice. It also focuses on Food and Drug Agency (FDA)-approved and clinically available radiopharmaceuticals rather than research tracers or those requiring a local cyclotron. This information will serve as a guide to primary providers for the appropriate role of PET-CT in managing patients with cutaneous malignancies, sarcomas and neuroendocrine tumors. The nuances of PET-CT interpretation as a practical guide for imaging providers, including radiologists, nuclear medicine physicians and their trainees, are also addressed.

show abstract

Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies

Schloemer,

Xue,

Qumseya

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundRhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Despite bone metastases being present in 5% of patients at diagnosis, there are limited studies examining these outcomes. We sought to define the prognostic factors, clinical courses, and outcomes of children treated on Children's Oncology Group (COG) clinical trials with RMS metastatic to bone at diagnosis.MethodsWe performed a retrospective analysis of patients diagnosed with bone metastatic RMS enrolled on COG RMS clinical trials (D9802, D9803, ARST0431, or ARST08P1) between 1997 and 2013.ResultsRMS metastatic to bone was identified in 154 patients at a median age of 14.9 years at diagnosis. Fifty‐eight percent of patients were male, 90% had metastases at additional sites, 74% had alveolar histology, and extremity was the most common primary site (31%). Eighty‐six percent of patients (n = 133) received radiation therapy. The 3‐ and 5‐year event‐free survival (EFS) was 15.4% and 14.5%, respectively. The 3‐ and 5‐year overall survival (OS) was 30.4% and 18.0%, respectively. We identified alveolar histology, FOXO1 fusion presence, unfavorable primary location, higher Oberlin score, and lack of radiation as poor prognostic characteristics for both EFS and OS in univariate analysis. Lack of radiation was not significant when excluding patients with events prior to 20 weeks.ConclusionsThis study is the largest analysis of patients with bone metastatic RMS, and defines the poor overall outcomes and negative prognostic factors for these patients. They may be eligible for therapy deintensification for improved quality of life or pursuit of novel treatments/approaches, which are desperately needed.

show abstract

Usefulness of 18f-FDG PET-CT in Staging, Restaging, and Response Assessment in Pediatric Rhabdomyosarcoma

Cited by 7 publications

References 24 publications

Paranasal Sinus Embryonal Rhabdomyosarcoma Metastasizing to Breast and Ovary on PET/CT—A Case Report with the Review of Literature

Paranasal Sinus Embryonal Rhabdomyosarcoma Metastasizing to Breast and Ovary on PET/CT—A Case Report with the Review of Literature

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies

Contact Info

Product

Resources

About